Roche has revealed about the success of an experimental drug which can prove to be a boon for the patients suffering from cancer. The drug is instrumental in blocking a protein that the gene produces in the cancerous cells.

The clinical trials of the drug were conducted at The Royal Marsden hospital in London and Surrey. The drug is beneficial in stopping the growth of skin cancer which can prove to be very dangerous.

Thus, it would helpful in increasing the overall survival of the patient. Even after surgery skin cancer returns and this happens in around 1,000 patients every year in Britain.

Scientists are of the view that no new drugs have been formulated over the last three decades. Roche is trying to get the Government's nod for marketing the drug which has been formulated by Plexxikon, a small biotechnology firm in Berkley, California.

Dr. Paul Chapman, an Oncologist at Memorial Sloan-Kettering Cancer Center who led the trial revealed that earlier they were using chemotherapy with the help of which they were able to know about things. However, now they have found the logical answer that will help them to progress further and save more lives.